4 years ago

Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test

ATHENA evaluated the cobas HPV Test as the primary screen for cervical cancer in women ≥25years. This reports the 3-year end-of-study results comparing the performance of HPV primary screening to different screening and triage combinations. Methods 42,209 women ≥25years were enrolled and had cytology and hrHPV testing. Women with abnormal cytology (≥atypical squamous cells of undetermined significance) and those HPV positive were referred to colposcopy. Women not reaching the study endpoint of CIN2+ entered the 3-year follow-up phase. Results 3-year CIR of CIN3+ in cytology-negative women was 0.8% (95% CI; 0.5–1.1%), 0.3% (95% CI 0.1–0.7%) in HPV-negative women, and 0.3% (95% CI; 0.1–0.6%) in cytology and HPV negative women. The sensitivity for CIN3+ of cytology was 47.8% (95% CI; 41.6–54.1%) compared to 61.7% (95% CI; 56.0–67.5%) for the hybrid strategy (cytology if 25–29years and cotesting with cytology and HPV if ≥30years) and 76.1% (95% CI; 70.3–81.8%) for HPV primary. The specificity for CIN3+ was 97.1% (95% CI; 96.9–97.2%), 94.6% (95% CI; 94.4–94.8%), and 93.5% (95% CI; 93.3–93.8%) for cytology, hybrid strategy, and HPV primary, respectively. Although HPV primary detects significantly more cases of CIN3+ in women ≥25years than either cytology or hybrid strategy, it requires significantly more colposcopies. However, the number of colposcopies required to detect a single CIN3+ is the same as for the hybrid strategy. Conclusions HPV primary screening in women ≥25years is as effective as a hybrid screening strategy that uses cytology if 25–29years and cotesting if ≥30years. However, HPV primary screening requires less screening tests.

Publisher URL: www.sciencedirect.com/science

DOI: S0090825814015492

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.